Type approval & clinical licence received for Siddharth-II Panacea received Type Approval and Clinical Licence from AERB for its Linear Accelerator- Siddharth-II in 2023. Panacea also received US 510(k) clearance of Siddharth-II integrated with RFA.
USFDA 510(k) received for Siddharth-II In 2021, Panacea received USFDA 510(k) clearance for Linear Accelerator- Siddharth-II.
Expanding Horizon In 2020, Panacea setup its a new state-of-art manufacturing plant in Malur and started its US operations in Indiana, USA as part of its expansion plan to cater to the increasing needs of Radiotherapy. Panacea also installed Bhabhatron MLC in Varanasi and Madurai
Linac – CE In 2019, Panacea’s Linear Accelerator was CE marked. Panacea also received patent for its Linac’s In gantry dual kV imaging
Lilac – CE In 2018, Bhabhatron II was installed in Uganda and Madagascar, ensuring timely treatment of cancer in these unreached areas. With Lilac getting CE marked in 2018, Panacea had empowered clinicians in the early detection of breast cancer.
Kassia Award In 2017, For its contribution, Panacea was awarded with Kassia Ujwala Prashasti Award and was certified with ZED
Improving Access By 2016, Panacea had left no stone unturned to improve access to radiotherapy with Bhabhatron II installed in Kenya, Tanzania and Kyrgyztan
66th Republic Day In 2015, A proud moment for Panacea when Bhabhatron II was displayed on Tableu on 66th Republic Day parade
Treating Lives With the donation of Bhabhatron II and Imagin to Mongolia, Bhabhatron II had treated more than 100,000 patients by 2014
Quality Award In 2013, Panacea Received quality award by Quality Council of India as recognition of Bhabhatron II’s success for cancer care